MRNA · 8-K · 20260731PR000147

Revenue Performance and Mix

Moderna, Inc. · 2026-07-31 · Importance 31 · Surprise 32 · No source text

Second-quarter 2026 revenue was $145 million, up 2% from $142 million in the second quarter of 2025. Net product sales declined to $94 million from $114 million, while other revenue increased to $51 million from $28 million. U.S. revenue was $87 million and international revenue was $58 million, with lower COVID vaccine sales offset by U.K. deliveries under a long-term government partnership and higher stand-ready manufacturing and collaboration revenue. Moderna is targeting up to 10% 2026 revenue growth and expects an approximately 50% U.S. and 50% international revenue split.

Key facts

• Moderna expects the 2026 revenue split to be approximately 50% U.S. and approximately 50% international. source
• Moderna expects approximately 55% of its second half 2026 revenue to be recognized in the third quarter. source
• Deferred revenue current was $295 million as of June 30, 2026 and deferred revenue non-current was $147 million. source
• Total revenue for the second quarter of 2026 was $145 million. source
• Revenue for the second quarter of 2026 was $87 million in the U.S. and $58 million in international markets. source
• Total revenue for the six months ended June 30, 2026 was $534 million. source
• Net product sales were $94 million for the three months ended June 30, 2026. source
• Other revenue was $51 million for the three months ended June 30, 2026. source

Impact estimates